Home > Insider Trading > Filing (0000899243-18-010684)

Filing Details

Accession Number:: 0000899243-18-010684
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-04-24 19:44:23
Reporting Period:: 2018-04-20

Accepted Time:: 2018-04-24 19:44:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1456589	Versant Ventures Iv, Llc	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456590	Versant Venture Capital Iv, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456591	Versant Side Fund Iv, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589095	Versant Affiliates Fund V, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589097	Versant Venture Capital V, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589098	Versant Ophthalmic Affiliates I, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1612235	Versant Venture Capital V (Canada), Lp	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2018-04-20	497,053	$0.00	2,238,979	No	4	J	Indirect	See footnote
Common Shares	Disposition	2018-04-20	2,947	$0.00	13,277	No	4	J	Indirect	See footnote
Common Shares	Acquisiton	2018-04-20	92,918	$0.00	92,918	No	4	J	Indirect	See footnote
Common Shares	Disposition	2018-04-20	92,918	$0.00	0	No	4	J	Indirect	See footnote
Common Shares	Disposition	2018-04-23	89,628	$50.66	1,539,576	No	4	S	Indirect	See footnote
Common Shares	Disposition	2018-04-23	2,630	$51.00	45,171	No	4	S	Indirect	See footnote
Common Shares	Disposition	2018-04-23	2,915	$51.00	50,072	No	4	S	Indirect	See footnote
Common Shares	Disposition	2018-04-23	6,821	$50.66	117,173	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.
These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.
Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.
These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.
Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV.
The shares are held by VV IV.
Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").
These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").
These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.("VVC CAN").
These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.